Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: Integrated analysis of cumulative data from 5 clinical trials

BMJ Open Respiratory Research

Volumn 3, Issue 1, 2016, Pages

  Lancaster, Lisa ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   Du Bois, Roland M ^e   Fagan, Elizabeth A ^c   Fishman, Robert S ^c   Glaspole, Ian ^f   Glassberg, Marilyn K ^g   King, Talmadge E ^h   Lederer, David J ⁱ   Lin, Zhengning ^c   Nathan, Steven D ^j   Pereira, Carlos A ^k   Swigris, Jeffrey J ^l   Valeyre, Dominique ^m   Noble, Paul W ⁿ  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j INOVA FAIRFAX HOSPITAL   (United States)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l DEPARTMENT OF MEDICINE   (United States)

^m AVICENNE HOSPITAL   (France)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PIRFENIDONE;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY;

EID: 85043559415     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2015-000105     Document Type: Article

References (11)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-8.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
4. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
5. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014;19:740-7.
6. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7.
7. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
8. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279-85.
9. Costabel U, Albera A, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:198-205.
10. Esbriet [summary of product characteristics]. London, UK: InterMune UK Ltd, 2011.
11. Esbriet ( pirfenidone) capsules, for oral use [package insert]. Brisbane, CA: InterMune, Inc, 2014.